At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
HZA106829: A Randomised, Double-blind, Parallel Group, Multicentre Study of Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder Alone, and Fluticasone Propionate Alone in the Treatment of Persistent Asthma in Adults and Adolescents
In Brief
A Phase 3 clinical trial evaluating Fluticasone Furoate/Vilanterol Inhalation Powder, Fluticasone Furoate Inhalation Powder, and 3 other interventions for Asthma. Completed, enrolled 587 participants across 71 sites in 6 countries.
Detailed Summary
The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persistent bronchial asthma over a 24-week period.
Study Details
Timeline
Interventions
Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
Placebo in novel dry powder inhaler once daily
Placebo in Diskus inhaler twice daily